The FDA's Pharmacy Compounding Advisory Committee voted to recommend that six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — be allowed for production by compounding pharmacies. FDA scientists had advised against this, citing insufficient evidence and safety concerns, yet the panel voted to proceed. Experts warn that compounding approval is not the same as FDA approval: major gaps remain in clinical data, long‑term safety (including cancer risk), and manufacturing standards, and many physicians say they would not prescribe these peptides until robust trials are available.
Advisory Panel Recommends Six Peptides for Compounding — Experts Urge Caution
Peptides May Soon Be Easier to GetGetty Images / Illustration
For Americans curious about longevity and recovery, peptides have long been an alluring but legally complicated option. A gray market has filled that gap: online vendors have sold popular peptides such as BPC-157 and TB-500, sometimes delivering the expected product and other times shipping tainted or mislabeled vials.
What the Panel Recommended
Late last week the FDA's Pharmacy Compounding Advisory Committee voted to recommend that six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — be added to the 503A bulk drug compounding list, which would allow compounding pharmacies to prepare them for patients under certain conditions. Additional regulatory steps remain (public comment review, a proposed rule, and White House sign-off), so availability via compounding, clinics, or prescriptions is still provisional.
Why This Move Is Unusual
Committee action here is notable for several reasons. FDA scientists had issued briefing documents advising against adding these peptides because of limited evidence and safety concerns — yet the advisory committee voted to proceed anyway. As Howard Sklamberg, a former FDA deputy commissioner, put it, the vote essentially overruled the agency's own scientists.
The committee's recent membership changes also drew scrutiny. In the weeks before the meeting, HHS Secretary Robert F. Kennedy Jr. appointed eight new members to the panel; six of the appointees reportedly have ties to the peptides industry. Critics say those connections appear to track closely with how members voted.
Evidence, Safety, and Manufacturing Concerns
Experts emphasize that committee approval for compounding is not the same as FDA approval. The typical FDA pathway requires rigorous clinical trials and ongoing post‑marketing surveillance to confirm safety, efficacy, and consistent manufacturing quality.
At present, high-quality clinical data for these peptides are scarce. Alexander E. Weber, MD, chief of sports medicine at Keck Hospital, and colleagues reviewing peptides for orthopedic recovery found "zero clinical data" supporting their effectiveness in humans. Without trials, clinicians and patients lack reliable information about dosing, benefits, or harms.
Cancer risk is a particular long-term concern. "Peptides do so many things — including regulating cell replication and death — that impact cancer risk," says Jennifer Manne-Goehler, MD. Longitudinal studies are needed to exclude harmful effects on cell‑growth pathways.
Manufacturing consistency is another problem. Compounded products typically rely on detailed monographs or defined compositions; without those standards, pharmacists may work from bulk material that lacks a validated specification. As Eileen J. Kennedy, PhD, explains, a small error in composition or structure can change a compound's effects or toxicity.
Compounded Drugs vs. FDA‑Approved Medications
FDA‑approved drugs are developed and produced under strict current good manufacturing practices (CGMP), undergo clinical testing, and participate in a robust adverse‑event surveillance system. Compounded medications generally face fewer manufacturing inspections and different quality controls. That gap raises the risk that once compounding begins, oversight may lag behind availability.
What Might Happen Next
If the FDA follows its advisory committee — which it often does — these peptides could become widely available through compounding within roughly a year or more, with some analysts estimating broader access by around 2027. Observers warn that wider availability without strong oversight and evidence could lead to harm before problems are detected.
Bottom Line
The advisory committee's recommendation could reduce the danger of patients buying unverified substances online, but it does not establish safety or effectiveness. Many clinicians interviewed — including Dr. Ramachandran, Dr. Weber, and Dr. Manne-Goehler — say they will not prescribe these peptides until rigorous clinical data exist. As one expert put it, the ethical imperative remains: "First do no harm."
Caveat: This story summarizes regulatory and scientific concerns about a developing policy. Patients should consult qualified clinicians and be wary of products obtained outside regulated channels.
Help us improve.
